Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Asheesh Lal (NPI 1841223047)

Field	Value
Entity Type	Individual
Organization	Asheesh Lal
Address	222 E Medical Ln Ste 400
City	West Columbia
State	SC
ZIP	29169
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 9, 2006

Payer Source	Total Paid
Medicare	$3.2M
Medicaid	$0

Key Findings

ASHEESH LAL is a Hematology & Oncology physician in WEST COLUMBIA, SC with total Medicare revenue of $3.2M and no Medicaid billing on file, making the practice effectively single‑payer (Medicare) in scale. The provider’s NPI was enumerated on 2006-07-09 (~20 years ago), indicating an established practice footprint over roughly two decades.

Revenue is highly concentrated in infusible oncology drugs: the precomputed top three Medicare codes (J9271, J9299, J0897) account for 51.9% of this provider’s Medicare revenue. Specifically, J9271 accounts for 27.0% of Medicare revenue, J9299 for 15.6%, and J0897 for 9.3%, signaling that a majority of billing dollars are driven by high-cost therapeutic injections.

The CPT/HCPCS mix points to an infusion-centered oncology practice focused on checkpoint inhibitors and monoclonal antibodies: high-revenue codes include J9271 (pembrolizumab), J9299 (nivolumab), J9144 (daratumumab), J9312 (rituximab) and J9035 (bevacizumab). The presence of supportive and hematologic agents such as J0897 (denosumab) and J2506 (pegfilgrastim) further indicates management of treatment-related bone and neutropenia risks typical of medical oncology infusion services.

Competitive standing is mixed by code: J9271 (20.2K claims, $828.2K revenue) ranks #383 of 1841 providers nationally (79th percentile; typical, unremarkable volume for this code), and J9299 ranks #165 of 505 providers nationally (67th percentile; typical, unremarkable volume for this code), suggesting typical national participation in checkpoint inhibitor use. In contrast, J0897 ranks #475 of 10057 providers nationally (95th percentile; notably above typical national volume for this code), and J9035 ranks #37 of 1852 providers nationally (98th percentile; notably above typical national volume for this code), indicating outsized use of certain agents relative to peers.

Operational footprints are reinforced by high-volume ancillary services: laboratory draws and panels appear frequently (85025, 36415, 80048, 80076), often ranking in the upper national percentiles (examples show 97th–99th percentile descriptors), which is consistent with an infusion center workflow that performs in‑office phlebotomy and routine lab monitoring. Chemotherapy administration (96413, 597 claims, $57.3K revenue) also ranks notably above typical national volume (#418 of 7514 providers; 94th percentile) and supports an active infusion practice.

Imaging and nuclear medicine utilization is notable for a physician-level oncology practice: A9595 (piflufolastat f-18) contributes $167.7K (5.5% of Medicare revenue) and ranks #161 of 528 providers nationally (69th percentile), while combined PET/CT (78815) contributes $136.9K (4.5% of Medicare revenue) and ranks #1076 of 6566 providers nationally (84th percentile). These entries indicate regular access to advanced diagnostic imaging for staging or treatment response assessment within the care pathway.

Payer mix and business risk are concentrated: with $3.2M reported Medicare revenue and “none below” for Medicaid, the practice lacks Medicaid-reimbursed volume on file and is therefore highly exposed to Medicare policy and reimbursement shifts. This single-payer concentration suggests the patient population served is primarily Medicare-eligible and that reimbursement changes at the Medicare level would disproportionately affect revenue.

Practice visit patterns include both new and established outpatient management: 99214 (536 claims, $49.3K revenue) ranks in the 91th percentile nationally and 99204 appears for new consults (65 claims, $7.3K revenue), indicating the provider performs moderate-complexity established visits alongside occasional new patient evaluations. The combination of E/M volume and high infusion/drug billing supports a practice model centered on longitudinal oncology management with in-office therapeutic delivery.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

90 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	20,200	$40	$828.2K
J9299	Injection, nivolumab, 1 mg	19,970	$20	$479.4K
J0897	Injection, denosumab, 1 mg	15,780	$20	$284K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	7,740	$40	$270.9K
J9173	Injection, durvalumab, 10 mg	3,050	$60	$189.3K
A9595	Piflufolastat f-18, diagnostic, 1 millicurie	360	$470	$167.7K
J9312	Injection, rituximab, 10 mg	2,540	$60	$159.8K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	190	$710	$136.9K
J9035	Injection, bevacizumab, 10 mg	1,590	$60	$89K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	960	$80	$74.9K

Showing 1–10 of 90

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 90 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Carolina Distribution

Asheesh Lal — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. state median

90 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	13	30	19,700	$40	$832K
J9299	4	10	15,760	$20	$432K
J9144	7	10	8,460	$40	$349.4K
J9173	3	10	3,050	$60	$275.9K
J9312	9	20	2,340	$60	$193.7K
A9595	7	10	410	$460	$175.9K
J0897	19	250	2,400	$20	$91.2K
J2506	5	10	740	$80	$55.9K
J1439	13	30	42,750	$1	$42.3K
Q5117	2	10	1,640	$20	$33.3K

Showing 1–10 of 90

Related Providers

Other providers that share a Tax Identification Number (TIN) with Asheesh Lal, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Lexington Health Inc	SC	General Acute Care Hospital	$0	$27.4M
Lexington County Health Services District Inc	SC	General Acute Care Hospital	$0	$19.2M
Lexington Health Inc	SC	Urgent Care Clinic/Center	$0	$8.7M
Lexington Health Inc	SC	Pediatric Adolescent Medicine Physician	$0	$5.7M
Lexington Health Inc	SC	Emergency Medicine Physician	$0	$4.2M
Lexington County Health Serv	SC	General Acute Care Hospital	$0	$4M
Steven Madden	SC	Hematology & Oncology Physician	$4M	$0
Lexington Health Inc	SC	Family Medicine Physician	$0	$4M
Lexington Health Inc	SC	Obstetrics & Gynecology Physician	$0	$3.5M
Vijaya Korrapati	SC	Hematology & Oncology Physician	$3.4M	$0

Nearby Providers

Other providers in the same ZIP code as Asheesh Lal, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Palmetto Infusion Services LLC	SC	Infusion Therapy Clinic/Center	$0	$93.6M
United Cerebral Palsy Of South Carolina, Inc	SC	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$15.7M
Palmetto Retina Center LLC	SC	Ophthalmology Physician	$0	$10.6M
Karen Park Family Dentistry, P.A.	SC	Dentist	$0	$4.2M
John Payne	SC	Ophthalmology Physician	$4M	$0
John Wells	SC	Ophthalmology Physician	$3.9M	$0
Lexington Treatment Specialists LLC	SC	Methadone Clinic	$76.7K	$3.6M
Perrie Ryan	SC	Hematology & Oncology Physician	$3.3M	$0
William Clark	SC	Ophthalmology Physician	$3.3M	$0
James Wells	SC	Hematology & Oncology Physician	$3.2M	$0

Asheesh Lal — Billing Profile & Reimbursement Data

Sign up for Asheesh Lal — Billing Profile & Reimbursement Data policy alerts

Asheesh Lal — Billing Profile & Reimbursement Data

Sign up for Asheesh Lal — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References